The secretagogue, the incretin-like, and the suppressive activities of long-chain fatty acids (LCFAs) in modulating insulin secretion in vivo and in cultured islets were simulated here by β,β′-tetramethyl-hexadecanedioic acid (M16) and α,α′-tetrachloro-tetradecanedioic acid (Cl-DICA). M16, but not Cl-DICA, serves as a substrate for ATP-dependent CoA thioesterification but is not further metabolized. M16, but not Cl-DICA, acted as a potent insulin secretagogue in islets cultured in basal but not high glucose. Short-term exposure to M16 or Cl-DICA resulted in activation of glucose- but not arginine-stimulated insulin secretion. Long-term exposure to M16, but not to Cl-DICA, resulted in suppression of glucose-, arginine-, and K+-stimulated insulin secretion; inhibition of glucose-induced proinsulin biosynthesis; and depletion of islets insulin. β-Cell mass and islet ATP content remained unaffected. Hence, nonmetabolizable LCFA analogs may highlight discrete LCFA metabolites and pathways involved in modulating insulin secretion, which could be overlooked due to the rapid turnover of natural LCFA.

Glucose-stimulated insulin secretion (GSIS) by β-cells is driven by closure of ATP-sensitive K+ channels (KATP channels) by glucose-generated ATP, resulting in cell membrane depolarization, activation of voltage-gated calcium channels (VGCCs), Ca+2 influx, and exocytosis of premade insulin granules (1). Ca+2 influx is further modulated by membrane repolarization induced by voltage-gated outward K+ currents (2). Long-chain fatty acids (LCFAs) affect insulin secretion as a function of exposure duration. Short-term exposure of β-cells to LCFA activates GSIS in vitro and in vivo, whereas long-term exposure results in blunted GSIS (3,4).

LCFA may activate insulin secretion by acting as primary secretagogues under conditions of basal glucose concentrations (5–7) or by amplifying insulin secretion when triggered by primary secretagogues like glucose, arginine, or KCl (8–10). The amplifying incretin-like activity of LCFA has been proposed to reflect increased levels of endogenous LCFA-CoA in excess of those maintained by inhibition of β-oxidation by glucose-derived malonyl-CoA (3). LCFA-CoAs were assumed to directly modulate effector systems involved in GSIS (e.g., VGCC [11], protein kinase C [PKC] [12], exocytosis proteins [13]) or to serve as a precursor of respective signaling lipids (e.g., diacylglycerol, phosphatidylinositol 4,5-bisphosphate) (3). The incretin-like activity of LCFA-CoA has been proposed to be further complemented by activation of G-protein coupled receptor 40 (GPR40) by the free-acid form of LCFA (14–16), resulting in Ca+2 mobilization, PKC activation, cAMP-dependent protein kinase activation (4), and inhibition of voltage-gated outward K+ currents (17). The physiological relevance of GSIS activation by short-term exposure to LCFAs in vivo is highlighted by the obligatory requirement for fatty acids in inducing insulin secretion by primary secretagogues following an overnight fast (18,19).

In contrast to activation of insulin secretion by short-term exposure to LCFAs, extended exposure to LCFAs may result in blunting insulin secretion in vivo (20–23) or in vitro (5,22,24). Inhibition of GSIS by LCFAs has been ascribed to inhibition of glucose metabolism due to glucose–fatty acid cycling (5), uncoupling of mitochondrial oxidative phosphorylation resulting in decreased yields of glucose-derived ATP (25), or β-cell lipotoxicity and apoptosis due to LCFA esterification into triglycerides and/or ceramides (26).

The modes of action of LCFAs in modulating insulin secretion by the respective free acids (e.g., uncoupling protein 2, GPR40), the respective fatty acyl-CoAs (e.g., KATP channel, VGCC, PKC), signaling lipids derived by LCFA esterification (e.g., diacylglycerol, phosphatidate, phosphatidylinositol 4,5-bisphosphate), or by β-oxidative metabolites that may evoke a Randle cycle still remain to be verified. To dissociate between the substrate and ligand effects of LCFAs and to define discrete pathways involved in the stimulus-exocytosis sequel of insulin secretion, the present study analyzes the mode of action of substituted α,ω-dicarboxylic acids (DICA compounds), namely β,β′-tetramethyl-hexadecanedioic acid (M16) and α,α′-tetrachloro-tetradecanedioic acid (Cl-DICA), in modulating insulin secretion in vivo and in culture. M16 [HOOC—CH2—C(CH3)2—(CH2)10—C(CH3)2—CH2—COOH] consists of an LCFA, carboxy substituted at the ω-end to block its esterification into lipids and methyl substituted at the β,β′ positions to block its β-oxidation (27,28). M16 may still be thioesterified in vivo to its respective acyl-CoA. In contrast to M16, Cl-DICA [HOOC—C(Cl)2—(CH2)10—C(Cl2)2—COOH] does not serve as a substrate for ATP-dependent CoA thioesterification (29,30) and may therefore simulate effects exerted by long-chain free fatty acids.

Animals and diets.

Sprague-Dawley male rats (Harlan) weighing 250–350 g were fed a standard powdered diet (55% carbohydrate, 20% protein, 4.5% fat, 12.1% moisture, 3.4% cellulose, and 5% ash). For long-term exposure to M16, animals were fed for 4 weeks with 390 mg M16/kg body wt mixed in the diet. For short-term exposure, animals were gavaged with a single dose of M16 or Cl-DICA (365 mg/kg body wt) in 1% (wt/vol) CMC (carboxy methyl cellulose). Animal care and experimental procedures were in accordance with guidelines of the animal care committee of the Hebrew University.

Hyperglycemic clamp and arginine-stimulated insulin secretion.

The tail artery and vein of fed animals were cannulated under local anesthesia using 1.5 ml of 2% lignocaine. Catheter patency was maintained with saline. Following recovery for 60 min, basal plasma insulin, C-peptide, and glucose were determined in two to three blood samples collected before secretagogue infusion. For hyperglycemic clamp, the animal was primed by infusing a glucose bolus (245 mg/kg) followed by maintaining blood glucose at 200 mg/dl for 49 min by variable infusion of 25% glucose in saline through the venous catheter. Blood samples were collected through the arterial catheter, every 2 min during the first 10 min and than every 3–8 min, into heparin tubes and kept on ice. Following 49 min of hyperglycemic clamp, glucose infusion was switched to saline supplemented with 2 ml washed red cells to replace blood loss, and the animals recovered for 60 min. Arginine-stimulated insulin secretion was primed by infusing a bolus of arginine (147 mg/kg body wt) through the venous catheter, followed by constant arginine infusion (4.5 mg/min) for 40 min. Blood samples were initially collected every 2 min during the first 10 min, followed by blood sampling every 5 min. Plasma samples were kept at −20°C for determination of insulin and C-peptide levels.

C-peptide clearance.

Animals cannulated as described above were primed by injecting a bolus mixture through the tail vein, consisting of 245 mg/kg body wt glucose and 147 mg/kg body wt arginine, followed by constant infusion of glucose and arginine at a rate of 34 and 18 mg · min−1 · kg−1 body wt, respectively. Following 10 min of constant infusion, C-peptide release was blocked by replacing the glucose-arginine infusion with an infusion of somatostatin (Sigma). The animals were first primed with a bolus of 5 μg/kg body wt somatostatin in 0.6% fatty acid–free BSA in saline, followed by somatostatin infusion at a rate of 0.4 μg · min−1 · kg−1 body wt. Blood samples were collected every 2.5 min, centrifuged, and kept at −20°C for determination of C-peptide levels.

β-Cell mass.

Rats were killed by cervical dislocation and pancreas excised and weighted, followed by an overnight fixation of a tissue sample in Bouin fixative. Pancreases were embedded in paraffin, and 5-μm sections were prepared at three depths separated by 300-μm intervals. The sections were incubated with guinea pig anti-pig insulin (Sigma), followed by goat anti–guinea pig cy5 (Jackson), and were scanned by fluorescent microscopy (Axiovert 100). Images were processed for β-cell area by Image Pro Plus. β-Cell mass was calculated by multiplying the percentage of β-cell area by total pancreatic weight.

Pancreas perfusion.

Animals were anesthetized with a ketamine (Fort Dodge, IA) xylazine (Biob, France) mixture. Pancreas perfusion was carried out as described by Penhos et al. (31). The perfusate consisted of a modified Krebs-Ringer bicarbonate buffer (pH 7.4) containing 4% dextran T70 (Sigma) and 0.2% BSA (fraction V) and was saturated with 95% O2/5% CO2. Following a 20-min recovery with perfusate containing 2.8 mmol/l glucose, samples were collected from the portal vein every 5 min for the next 20 min, followed by switching to 17.0 mmol/l glucose for the next 30 min. Samples were collected every 2.5 min for the first 10 min and then every 5 min. Perfusate samples were centrifuged and the supernatant kept at −20°C for determination of insulin and C-peptide levels. Perfusions were terminated by perfusing the pancreas with Trypan Blue to determine the extent of pancreas perfusion. Only experiments in which the whole pancreas was stained with Trypan Blue were further processed.

Insulin secretion and insulin content in islets.

Pancreatic islets were isolated as described by Sutton et al. (32) using collagenase P (Roche Diagnostics). Islets were digested and washed in Hank’s solution containing 5.5 mmol/l glucose, handpicked under binocular, and cultured in five batches of five islets in 24-well Nunc plates containing RPMI 1640 (Sigma) supplemented with 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 10% (vol/vol) FCS (Biological Industries) in the presence of 2.8 or 11.2 mmol/l glucose, as indicated, in the absence or presence of 250 μmol/l M16 or Cl-DICA, as indicated. Medium samples were collected as indicated to assess cumulative insulin release. Following 48 h in culture, the islets were washed, preincubated for 60 min in Krebs-Ringer buffer containing 10 mmol/l HEPES, 0.5% fatty acid–free BSA (KRBH-BSA), and 2.8 mmol/l glucose and were subsequently subjected to GSIS, K+-stimulated insulin secretion (KSIS), or arginine-stimulated insulin secretion (ArgSIS) in 24-well plates as indicated. For GSIS, the islets were incubated for 45 min in 600 μl KRBH-BSA containing either 2.8 or 20 mmol/l glucose. For KSIS, the islets were incubated for 45 min in 600 μl KRBH-BSA containing 2.8 mmol/l glucose and 30 mmol/l KCl. For ArgSIS, the islets were incubated for 45 min in 600 μl KRBH-BSA containing 2.8 mmol/l glucose and 20 mmol/l arginine. Samples were kept at −20°C for determination of insulin levels. Following incubation, the islets were extracted with 200 μl acidic ethanol (1.8 mol/l HCl in 75% ethanol) and sonicated. The extracts were kept overnight at 4°C, centrifuged, and the supernatant was kept in −20°C for determination of islets insulin content.

Islet ATP content.

Batches of 10 islets cultured for 48 h in 11.2 mmol/l glucose in the presence or absence of 250 μmol/l M16 were incubated in KRBH-BSA containing 0.5 or 20 mmol/l glucose as indicated, followed by extraction with trichloroacetic acid (5% final concentration). The extract was immediately mixed, placed on ice for 15 min, and centrifuged. The supernatant (400 μl) was extracted three times with 1.2 ml diethyl ether, and 0.2 ml of the washed extract were diluted with 0.2 ml buffer containing 20 mmol/l HEPES (pH 7.75) and 3 mmol/l MgCl2 and kept at −80°C for determination of ATP levels.

Proinsulin biosynthesis in islets.

Batches of 25 islets were cultured in RPMI medium containing 2.8 or 11.2 mmol/l glucose in the presence or absence of 250 μmol/l M16. Following 48 h in culture, the islets were centrifuged and further incubated for 15 min in KRBH-BSA supplemented with 2.8 or 11.2 mmol/l glucose containing 25 μCi of l-[2,3,4,5-3H]leucine (120 Ci/mmol s.a.) (American Radiolabeled Chemicals, St. Louis, MO). Incorporation of radioactive leucine into proinsulin and total protein was measured as described by Leibowitz et al. (33).

Assays.

ATP was assayed using a luminometric method (BioLab kit). C-peptide was assayed by radioimmunoassay (RIA) using rat C-peptide kit (Linco, St. Charles, MO). Insulin was assayed by RIA using anti-insulin–coated tubes (ICN Pharmaceuticals, Costa Mesa, CA) and 125I insulin (Linco). Insulin RIA was calibrated by rat insulin.

DICA compounds in vivo

Short-term exposure.

Effects of short-term exposure to LCFA analogs in vivo were verified in rats administered a single dose of vehicle, M16, or Cl-DICA and subjected to hyperglycemic (11.2 mmol/l glucose) clamp, 2 h following drug administration. Short-term exposure to M16 resulted in an increase in basal plasma C-peptide levels (Table 1). Short-term exposure to M16 and Cl-DICA resulted in twofold activation of insulin and C-peptide secretion under hyperglycemic clamp conditions (Table 1). The ratio of plasma C-peptide to insulin remained unaffected during the clamp, indicating that the observed increases in plasma insulin and C-peptide levels were accounted for by activation of insulin secretion rather than modulation of its plasma clearance. Activation of insulin secretion by M16 or Cl-DICA was glucose specific and not induced when using arginine as the primary secretagogue (Table 1).

Long-term exposure.

Treatment of rats for 4 weeks with M16 did not affect body weight or fasting plasma glucose levels but resulted in nonsignificant decrease in plasma insulin and plasma C-peptide (Table 2). Extended exposure to M16 resulted in a robust decrease in total and first-phase insulin and C-peptide secretion under hyperglycemic (11.2 mmol/l glucose) clamp conditions (Table 2). GSIS suppression by M16 was accompanied by a 28% increase in the ratio of secreted C-peptide to insulin (Table 2), indicating that suppression of plasma insulin levels in response to long-term exposure to M16 was partly accounted for by selective activation of plasma insulin clearance, which is in line with our previous findings in M16-treated fa/fa rats (34). However, plasma C-peptide clearance by renal excretion remained unaffected in treated animals (0.13 ± 0.01 vs. 0.11 ± 0.01 pmol · l−1 · min−1 in nontreated and M16-treated animals, respectively), thus implying genuine suppression of GSIS by chronic exposure to M16. Suppression of insulin secretion by extended exposure to M16 was similarly observed on arginine-induced depolarization (Table 2), implicating the involvement of M16 in a step beyond KATP channels in the stimulus-exocytosis coupling pathway.

Suppression of GSIS by long-term exposure to M16 in vivo was further verified under conditions of pancreas perfusion in situ. Basal (3.0 mmol/l glucose) insulin secretion remained unaffected, while GSIS (17.0 mmol/l glucose) decreased by 36% in M16-treated animals (7,756 ± 577 and 4,963 ± 828 ng/30 min [n = 7] in nontreated and M16-treated animals, respectively, P < 0.05 by t test), indicating that suppression of GSIS by long-term exposure to M16 in vivo was not mediated by a washable humoral factor.

Suppression of insulin secretion by chronic exposure to M16 in vivo was accompanied by depletion of islets’ insulin (Table 3). Insulin secretion and islets’ insulin content were suppressed to a similar extent by chronic exposure to M16, thus indicating possible linkage between the two functions. However, β-cell mass, the mean area of β-cell clusters, and the density of β-cell clusters remained unaffected in M16-treated animals (Table 3). Hence, suppression of insulin secretion by chronic exposure to M16 in vivo may imply its involvement in β-cell function rather than β-cell mass.

DICA compounds in cultured islets

Insulin secretion.

Suppression of insulin secretion by extended exposure to M16 was further verified in rat islets cultured for 48 h with added M16 (250 μmol/l) in 11.2 mmol/l glucose. Following culturing, the islets were washed in KRBH-BSA containing 2.8 mmol/l glucose, followed by measuring insulin secretion induced by 20 mmol/l glucose (GSIS), 20 μmol/l arginine (in 2.8 mmol/l glucose) (ArgSIS), or 30 mmol/l KCl (in 2.8 mmol/l glucose) (KSIS) in the absence of M16. Basal (2.8 mmol/l glucose) insulin secretion remained essentially unaffected by prior exposure to M16 in the presence of high glucose (11.2 mmol/l). However, GSIS, KSIS, or ArgSIS were robustly suppressed by M16 (Fig. 1A), which is in line with suppression of insulin secretion in vivo by chronic exposure to M16 (Table 2). In contrast to M16, GSIS remained unaffected by exposure of islets to Cl-DICA (Fig. 1B), pointing to a requirement for the respective acyl-CoA. Suppression of insulin secretion by M16 was not accounted for by decrease in islets’ basal or glucose-stimulated ATP content (Fig. 1C).

Suppression of insulin secretion in islets cultured with M16 required the concomitant presence of added glucose (>2.8 mmol/l) during exposure to M16. Thus, insulin secretion in response to glucose remained unaffected by M16 in islets cultured in the presence of basal glucose (2.8 mmol/l) (Fig. 2A). Furthermore, long-term exposure to M16 in basal glucose resulted in M16-stimulated insulin secretion (M16SIS) (Fig. 2A). The mutual relationship between M16 and glucose, namely the requirement for high glucose (11.2 mmol/l) for suppression of insulin secretion by M16 and suppression of M16SIS by high glucose, was further verified by measuring insulin secretion into the culture medium during a 48-h exposure to M16. Exposure to M16 under conditions of basal glucose resulted in robust progressive secretion of insulin to the culture medium, whereas insulin secretion remained unaffected by M16 under conditions of high glucose (Fig. 2B and C). In contrast to M16SIS, insulin secretion by islets cultured in basal glucose remained unaffected by exposure to Cl-DICA (data not shown).

Insulin content and biosynthesis.

Extended exposure of islets to M16 (250 μmol/l) resulted in moderate decrease in insulin content in islets cultured in low (2.8 mmol/l) glucose (1,082 ± 114 and 808 ± 102 ng/five islets [n = 4] in nontreated and M16-treated islets, respectively, P < 0.01 by paired t test) and in pronounced decrease in islets cultured in high (11.2 mmol/l) glucose (1,208 ± 108 and 625 ± 86 ng/five islets [n = 14] in nontreated and M16-treated islets, respectively, P < 0.0005 by t test). Insulin secretion and islets’ insulin content were suppressed to a similar extent by extended exposure to M16, as reflected by the ratio of insulin secretion (45 min) to islets’ insulin content (4.0 ± 0.02% [n = 7] and 3.7 ± 0.02% [n = 7] in nontreated and in islets exposed to 250 μmol/l M16 for 48 h, respectively), thus indicating possible linkage between the two functions. M16-induced decreases in islets’ insulin content under conditions of basal glucose could essentially be accounted for by the robust increase in insulin secretion prompted by M16 (M16SIS) (Fig. 2). M16-induced decreases in islets’ insulin content under conditions of culturing the islets in high glucose could be ascribed to M16 suppression of glucose-induced insulin biosynthesis, combined with depletion of pancreatic insulin due to sustained hyperglycemia. Indeed, proinsulin biosynthesis was inhibited by 40% in islets cultured with M16 in 11.2 mmol/l glucose but not in islets cultured in 2.8 mmol/l glucose (Fig. 3), thus accounting for the decrease in insulin content induced by M16 under conditions of high glucose. The role played by sustained hyperglycemia in depleting pancreatic insulin was evaluated by culturing the islets in the presence of diazoxide. Suppression of GSIS by M16 in islets cultured for 48 h in high glucose was blunted in the presence of added diazoxide, with concomitant blunted depletion of pancreatic insulin (Fig. 4), indicating that suppression of GSIS by M16 in islets cultured in high glucose was partly accounted for by sustained insulin depletion.

The mode of action of DICA compounds in the β-cell context has been verified here in order to define discrete LCFA metabolites and pathways involved in modulating insulin secretion during short-term or extended exposure to LCFAs. Since DICA compounds are essentially not metabolized, they may highlight LCFA effects, which could be masked by the rapid turnover of natural LCFAs. Furthermore, since Cl-DICA does not serve as a substrate for CoA thioesterification, it may simulate long-chain free fatty acids, while M16 may simulate effects exerted by the free acid, as well as the acyl-CoA thioester of LCFA (29,30). It should be pointed out, however, that quantitative differences between M16 and Cl-DICA could result from respective differences in their intracellular concentrations due to the intracellular entrapment of M16-CoA but not of free Cl-DICA acid.

The short-term incretin-like activity of amphipathic carboxylates.

It is reported here that a single dose of M16 or Cl-DICA results in activation of glucose but not ArgSIS in vivo, thus implicating an early glucose-specific step in activation of the stimulus-exocytosis coupling pathway by LCFAs. Activation of GSIS by short-term exposure to either M16 or Cl-DICA, in spite of the nonavailability of Cl-DICA for CoA thioesterification, may imply that their free-acid form, rather than the respective acyl-CoA, mediates activation of GSIS by DICA or LCFA. The incretin-like amplifying activity of free LCFAs, in the specific context of insulin secretion stimulated by glucose as a primary secretagogue, may specifically implicate GPR40 activation. This proposed mode of action is corroborated by the 1) previously reported activation of GPR40 by M16 (16), 2) specific requirement for GPR40 for the incretin-like activity of LCFAs, as verified in GPR40−/− mice (35), and 3) specific requirement for the presence of high glucose for GPR40 effects in β-cells (36).

The incretin-like activity of free LCFA transduced by GPR40 may apparently imply that endogenous LCFA-CoAs maintained by glucose-derived malonyl-CoA (37) play a minor role, if any, in promoting GSIS. This is in line with 1) GSIS being unaffected by overexpressed malonyl-CoA decarboxylase (38, but see 39, where overexpression of malonyl-CoA decarboxylase was claimed to suppress GSIS in the presence of added exogenous free fatty acid, but not in their absence), 2) dumping of LCFA-CoA levels by high glucose (40), and 3) Kir6.2 gating by LCFA-CoAs (11,41). It is noteworthy, however, that in light of its glucose specificity, the incretin-like activity of M16 free acid or Cl-DICA (Table 1) may not account for the reported activity of LCFAs in amplifying insulin secretion induced by KCl or arginine (8) or the reported obligatory requirement for LCFAs in KSIS or ArgSIS in fasted rats in vivo (42). Hence, the incretin-like activity of LCFA is proposed to be transduced by two complementary transduction pathways: namely, activation of a glucose-specific early step of insulin secretion transduced by GPR40 and mediated by free LCFAs and activation of a late step in the stimulus-exocytosis sequel, mediated by an LCFA metabolite downstream of acyl-CoA.

The secretagogue activity of amphipathic carboxylates.

In addition to activation of GSIS by short-term exposure to LCFAs or DICA compounds, LCFA and M16 (Fig. 2) activate insulin secretion as primary secretagogues, namely under conditions of basal glucose (6–8). The following differences between the incretin-like and the secretagogue characteristics of LCFAs in the β-cell context are noteworthy. The secretagogue activity is blunted by high glucose (Fig. 2), being replaced by the secretagogue activity of glucose itself. In contrast, the incretin-like activity of M16 prevails under conditions of high glucose (Table 1). The secretagogue activity of amphipathic carboxylates initiated by short-term exposure may proceed on extended exposure (Fig. 2B and C). In contrast, the incretin-like activity is conditioned by short-term exposure, being replaced by suppression of GSIS on extended exposure. Unlike the incretin-like effect, the secretagogue activity is not induced by Cl-DICA, indicating that it is transduced by the acyl-CoA rather than the free-acid form of LCFA. This is corroborated by the previously reported partial inhibition of the secretagogue activity of LCFA by Triacsin C (43). The secretagogue activity of M16 is negligent in vivo compared with glucose (Table 1) and is mostly evident in islets, where it approaches the secretagogue activity of glucose (Fig. 2). In contrast, the incretin-like activity of M16 is of most significance in vivo (Table 1). These differences between the secretagogue and the incretin-like activities of amphipathic carboxylates in the β-cell context may indicate that in spite of their apparent similarity in activating insulin secretion, the two activities are transduced by unique pathways.

Suppression of insulin secretion by amphipathic carboxylates.

Extended exposure to LCFA or M16 results in depletion of insulin stores (5,6), suppressed proinsulin biosynthesis (5,6,44,45), and suppressed insulin secretion in response to glucose (5). Insulin depletion and suppression of insulin secretion were partly alleviated by adding diazoxide (46). Inhibition of insulin secretion by extended exposure to M16 was characterized by 1) suppression of GSIS, KSIS, or ArgSIS, implicating the involvement of a late step in the stimulus-exocytosis coupling pathway, beyond KATP channels; 2) requirement for the concomitant presence of high glucose in culture (Figs. 1A and2A); and 3) specificity for M16, whereas Cl-DICA was inactive, thus implicating a requirement for the acyl-CoA form of LCFA.

Suppression of insulin secretion by extended exposure to LCFAs has been previously ascribed to lipotoxicity due to loading β-cells with triglycerides and/or lipotoxic lipids (e.g., ceramides) (24,26,47), to blunted glucose-induced ATP production as a result of LCFA-induced Randle cycle (5), to uncoupling of mitochondrial oxidative phosphorylation (48), or to direct gating of Kir6.2 channels by LCFA-CoA (11). Suppression of insulin secretion by M16 may help in evaluating some of these proposed modes of action. Thus, since M16-CoA is not esterified into lipids, its suppression of insulin secretion may not be ascribed to putative lipotoxic products, which is in line with the preservation of β-cell mass and pancreatic morphology in M16-treated animals and in corroboration with Boucher et al. (49). Similarly, since M16-CoA is not β-oxidized, its suppression of insulin secretion is not accounted for by putative β-oxidation products that may inhibit glucose uptake and its utilization, which is in line with previous reports (5,44,50). Also, maintenance of intracellular ATP levels in M16-treated islets may further refute M16 effects due to uncoupling of oxidative phosphorylation. Lack of suppression by Cl-DICA may indicate that suppression of insulin secretion by LCFA or M16 is mediated by the respective acyl-CoAs, targeting a downstream element in the stimulus-exocytosis coupling pathway that still remains to be defined.

In conclusion, the use of DICA compounds may help in verifying the characteristics and concerned transduction pathways that may transduce the incretin-like secretagogue and the suppressive activities of LCFA in the β-cell context. The incretin-like activity induced by short-term exposure is glucose specific, appears to be mediated by the free acid rather than the acyl-CoA, and is proposed to be transduced by activation of GPR40. The secretagogue activity is blunted by high glucose, maintained during extended exposure, is mostly evident in cultured islets, and transduced by the acyl-CoA. Suppression of glucose, K+, or ArgSIS by extended exposure is induced under conditions of high glucose, accompanied by inhibition of glucose-induced proinsulin biosynthesis, and mediated by the acyl-CoA. The respective acyl-CoA target(s) remain to be identified.

FIG. 1.
FIG. 1. Suppression of insulin secretion by M16 in islets cultured in high glucose. A: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring insulin secretion in response to either 2.8 or 20 mmol/l glucose (n = 12) or in response to 20 mmol/l arginine (n = 3) or 30 mmol/l KCl (n = 3) in the presence of 2.8 mmol/l glucose as described in research design and methods. Means ± SE. *Significant compared with nontreated islets (P < 0.05 by t test). B: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence of 250 μmol/l M16 (□) or Cl-DICA (), followed by measuring insulin secretion in response to 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with nontreated islets (P < 0.05 by ANOVA/two-by-two comparison). C: Islets were cultured for 48 h in 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring islets’ ATP content in response to 0.5 or 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with respective 0.5 mmol/l glucose (P < 0.05 by t test).
View largeDownload slide

Suppression of insulin secretion by M16 in islets cultured in high glucose. A: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring insulin secretion in response to either 2.8 or 20 mmol/l glucose (n = 12) or in response to 20 mmol/l arginine (n = 3) or 30 mmol/l KCl (n = 3) in the presence of 2.8 mmol/l glucose as described in research design and methods. Means ± SE. *Significant compared with nontreated islets (P < 0.05 by t test). B: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence of 250 μmol/l M16 (□) or Cl-DICA (), followed by measuring insulin secretion in response to 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with nontreated islets (P < 0.05 by ANOVA/two-by-two comparison). C: Islets were cultured for 48 h in 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring islets’ ATP content in response to 0.5 or 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with respective 0.5 mmol/l glucose (P < 0.05 by t test).

FIG. 1.
FIG. 1. Suppression of insulin secretion by M16 in islets cultured in high glucose. A: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring insulin secretion in response to either 2.8 or 20 mmol/l glucose (n = 12) or in response to 20 mmol/l arginine (n = 3) or 30 mmol/l KCl (n = 3) in the presence of 2.8 mmol/l glucose as described in research design and methods. Means ± SE. *Significant compared with nontreated islets (P < 0.05 by t test). B: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence of 250 μmol/l M16 (□) or Cl-DICA (), followed by measuring insulin secretion in response to 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with nontreated islets (P < 0.05 by ANOVA/two-by-two comparison). C: Islets were cultured for 48 h in 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring islets’ ATP content in response to 0.5 or 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with respective 0.5 mmol/l glucose (P < 0.05 by t test).
View largeDownload slide

Suppression of insulin secretion by M16 in islets cultured in high glucose. A: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring insulin secretion in response to either 2.8 or 20 mmol/l glucose (n = 12) or in response to 20 mmol/l arginine (n = 3) or 30 mmol/l KCl (n = 3) in the presence of 2.8 mmol/l glucose as described in research design and methods. Means ± SE. *Significant compared with nontreated islets (P < 0.05 by t test). B: Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence of 250 μmol/l M16 (□) or Cl-DICA (), followed by measuring insulin secretion in response to 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with nontreated islets (P < 0.05 by ANOVA/two-by-two comparison). C: Islets were cultured for 48 h in 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring islets’ ATP content in response to 0.5 or 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 3). *Significant compared with respective 0.5 mmol/l glucose (P < 0.05 by t test).

Close modal
FIG. 2.
FIG. 2. Activation of insulin secretion by M16 in islets cultured in basal glucose. A: Islets were cultured for 48 h in 2.8 mmol/l glucose in the absence (▪) or presence (□) of 250 mmol/l M16, followed by measuring insulin secretion in response to 2.8 and 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 4). *Significant compared with nontreated islets cultured and assayed in 2.8 mmol/l glucose (P < 0.05 by t test). B. Islets were cultured for 24 h in medium containing 2.8 (circles), 5.6 (triangles), or 11.2 mmol/l (squares) glucose, in the absence (filled symbols) or presence (open symbols) of 250 μmol/l M16. Cumulative insulin secretion into the medium was measured following 1, 2, 3, and 24 h in culture. Representative experiment. C: Cumulative insulin secretion during 48 h. Conditions are the same as in B. Means ± SE for five independent experiments. *Significant compared with total insulin release for the respective glucose concentration (P < 0.01 by t test).
View largeDownload slide

Activation of insulin secretion by M16 in islets cultured in basal glucose. A: Islets were cultured for 48 h in 2.8 mmol/l glucose in the absence (▪) or presence (□) of 250 mmol/l M16, followed by measuring insulin secretion in response to 2.8 and 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 4). *Significant compared with nontreated islets cultured and assayed in 2.8 mmol/l glucose (P < 0.05 by t test). B. Islets were cultured for 24 h in medium containing 2.8 (circles), 5.6 (triangles), or 11.2 mmol/l (squares) glucose, in the absence (filled symbols) or presence (open symbols) of 250 μmol/l M16. Cumulative insulin secretion into the medium was measured following 1, 2, 3, and 24 h in culture. Representative experiment. C: Cumulative insulin secretion during 48 h. Conditions are the same as in B. Means ± SE for five independent experiments. *Significant compared with total insulin release for the respective glucose concentration (P < 0.01 by t test).

FIG. 2.
FIG. 2. Activation of insulin secretion by M16 in islets cultured in basal glucose. A: Islets were cultured for 48 h in 2.8 mmol/l glucose in the absence (▪) or presence (□) of 250 mmol/l M16, followed by measuring insulin secretion in response to 2.8 and 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 4). *Significant compared with nontreated islets cultured and assayed in 2.8 mmol/l glucose (P < 0.05 by t test). B. Islets were cultured for 24 h in medium containing 2.8 (circles), 5.6 (triangles), or 11.2 mmol/l (squares) glucose, in the absence (filled symbols) or presence (open symbols) of 250 μmol/l M16. Cumulative insulin secretion into the medium was measured following 1, 2, 3, and 24 h in culture. Representative experiment. C: Cumulative insulin secretion during 48 h. Conditions are the same as in B. Means ± SE for five independent experiments. *Significant compared with total insulin release for the respective glucose concentration (P < 0.01 by t test).
View largeDownload slide

Activation of insulin secretion by M16 in islets cultured in basal glucose. A: Islets were cultured for 48 h in 2.8 mmol/l glucose in the absence (▪) or presence (□) of 250 mmol/l M16, followed by measuring insulin secretion in response to 2.8 and 20 mmol/l glucose as described in research design and methods. Means ± SE (n = 4). *Significant compared with nontreated islets cultured and assayed in 2.8 mmol/l glucose (P < 0.05 by t test). B. Islets were cultured for 24 h in medium containing 2.8 (circles), 5.6 (triangles), or 11.2 mmol/l (squares) glucose, in the absence (filled symbols) or presence (open symbols) of 250 μmol/l M16. Cumulative insulin secretion into the medium was measured following 1, 2, 3, and 24 h in culture. Representative experiment. C: Cumulative insulin secretion during 48 h. Conditions are the same as in B. Means ± SE for five independent experiments. *Significant compared with total insulin release for the respective glucose concentration (P < 0.01 by t test).

Close modal
FIG. 3.
FIG. 3. Islets proinsulin biosynthesis. Islets were cultured for 48 h in medium containing 2.8 or 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring total proinsulin biosynthesis (A), total protein biosynthesis (B), and specific proinsulin biosynthesis (total proinsulin/total protein biosynthesis) (C) in 2.8 or 11.2 mmol/l glucose as described in research design and methods. The data represent fold biosynthesis compared with biosynthesis assayed in 2.8 mmol/l glucose in control islets. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).
View largeDownload slide

Islets proinsulin biosynthesis. Islets were cultured for 48 h in medium containing 2.8 or 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring total proinsulin biosynthesis (A), total protein biosynthesis (B), and specific proinsulin biosynthesis (total proinsulin/total protein biosynthesis) (C) in 2.8 or 11.2 mmol/l glucose as described in research design and methods. The data represent fold biosynthesis compared with biosynthesis assayed in 2.8 mmol/l glucose in control islets. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).

FIG. 3.
FIG. 3. Islets proinsulin biosynthesis. Islets were cultured for 48 h in medium containing 2.8 or 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring total proinsulin biosynthesis (A), total protein biosynthesis (B), and specific proinsulin biosynthesis (total proinsulin/total protein biosynthesis) (C) in 2.8 or 11.2 mmol/l glucose as described in research design and methods. The data represent fold biosynthesis compared with biosynthesis assayed in 2.8 mmol/l glucose in control islets. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).
View largeDownload slide

Islets proinsulin biosynthesis. Islets were cultured for 48 h in medium containing 2.8 or 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16, followed by measuring total proinsulin biosynthesis (A), total protein biosynthesis (B), and specific proinsulin biosynthesis (total proinsulin/total protein biosynthesis) (C) in 2.8 or 11.2 mmol/l glucose as described in research design and methods. The data represent fold biosynthesis compared with biosynthesis assayed in 2.8 mmol/l glucose in control islets. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).

Close modal
FIG. 4.
FIG. 4. Effect of diazoxide on islets’ insulin secretion and content. Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16 and in the presence or absence of 100 μmol/l diazoxide as indicated, followed by measuring insulin content (A) and insulin secretion in response to 20 mmol/l glucose (B) as described in research design and methods. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).
View largeDownload slide

Effect of diazoxide on islets’ insulin secretion and content. Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16 and in the presence or absence of 100 μmol/l diazoxide as indicated, followed by measuring insulin content (A) and insulin secretion in response to 20 mmol/l glucose (B) as described in research design and methods. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).

FIG. 4.
FIG. 4. Effect of diazoxide on islets’ insulin secretion and content. Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16 and in the presence or absence of 100 μmol/l diazoxide as indicated, followed by measuring insulin content (A) and insulin secretion in response to 20 mmol/l glucose (B) as described in research design and methods. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).
View largeDownload slide

Effect of diazoxide on islets’ insulin secretion and content. Islets were cultured for 48 h in medium containing 11.2 mmol/l glucose in the absence (▪) or presence (□) of 250 μmol/l M16 and in the presence or absence of 100 μmol/l diazoxide as indicated, followed by measuring insulin content (A) and insulin secretion in response to 20 mmol/l glucose (B) as described in research design and methods. Means ± SE (n = 4). *Significant compared with respective nontreated islets (P < 0.05 by t test).

Close modal
TABLE 1

Activation of insulin secretion by short-term exposure to DICA compounds in vivo

M16
Cl-DICA
NontreatedM16 treatedNontreatedCl-DICA treated
Basal     
    Insulin (pmol/l) 294 ± 45 284 ± 22 410 ± 46 212 ± 30* 
    C-peptide (pmol/l) 773 ± 84 1,170 ± 117* 949 ± 114 736 ± 102 
    Gluocse (mg/dl) 102 ± 1 102 ± 2 96 ± 6 91 ± 6 
Hyperglycemic clamp     
    Glucose AUC 9,837 ± 119 9,805 ± 111 10,393 ± 82 10,204 ± 81 
    Insulin AUC 30,690 ± 4,244 61,707 ± 8,185* 30,429 ± 5,593 60,445 ± 14,847* 
    C-peptide AUC 60,181 ± 4,695 120,419 ± 8,592* 63,777 ± 5,717 130,065 ± 20,032* 
    C-peptide AUC/insulin AUC 2.03 ± 0.17 1.91 ± 0.12 2.08 ± 0.16 2.15 ± 0.15 
Arginine stimulation     
    Insulin AUC 21,600 ± 4,350 22,650 ± 2,100 15,421 ± 2,107 19,306 ± 3,241 
    C-peptide AUC 42,246 ± 7,896 50,550 ± 5,123 35,752 ± 3,636 44,361 ± 2,532 
M16
Cl-DICA
NontreatedM16 treatedNontreatedCl-DICA treated
Basal     
    Insulin (pmol/l) 294 ± 45 284 ± 22 410 ± 46 212 ± 30* 
    C-peptide (pmol/l) 773 ± 84 1,170 ± 117* 949 ± 114 736 ± 102 
    Gluocse (mg/dl) 102 ± 1 102 ± 2 96 ± 6 91 ± 6 
Hyperglycemic clamp     
    Glucose AUC 9,837 ± 119 9,805 ± 111 10,393 ± 82 10,204 ± 81 
    Insulin AUC 30,690 ± 4,244 61,707 ± 8,185* 30,429 ± 5,593 60,445 ± 14,847* 
    C-peptide AUC 60,181 ± 4,695 120,419 ± 8,592* 63,777 ± 5,717 130,065 ± 20,032* 
    C-peptide AUC/insulin AUC 2.03 ± 0.17 1.91 ± 0.12 2.08 ± 0.16 2.15 ± 0.15 
Arginine stimulation     
    Insulin AUC 21,600 ± 4,350 22,650 ± 2,100 15,421 ± 2,107 19,306 ± 3,241 
    C-peptide AUC 42,246 ± 7,896 50,550 ± 5,123 35,752 ± 3,636 44,361 ± 2,532 

Data are means ± SE. Sprague-Dawley rats were treated orally by gavage with a single dose of M16 (365 mg/kg body wt) or Cl-DICA (365 mg/kg body wt) and were subjected 2 h later to hyperglycemic clamp followed by arginine infusion as described in research design and methods. Data are for five nontreated and five treated rats.

*

Significant compared with respective nontreated parameters (P < 0.05 by Mann-Whitney test). AUC, area under the glucose (mg/dl × min), insulin (pmol/l × min), and C-peptide (pmol/l × min) curves.

View Large
TABLE 2

Suppression of insulin secretion by extended exposure to M16 in vivo

BasalM16 treatedNontreatedM16 treatedNontreated
    Insulin (pmol/l) 307 ± 41 341 ± 55   
    C-peptide (pmol/l) 773 ± 91 970 ± 108   
    Glucose (mg/dl) 110 ± 3 99 ± 6   
BasalM16 treatedNontreatedM16 treatedNontreated
    Insulin (pmol/l) 307 ± 41 341 ± 55   
    C-peptide (pmol/l) 773 ± 91 970 ± 108   
    Glucose (mg/dl) 110 ± 3 99 ± 6   
First-phase AUC
Total AUC
Hyperglycemic clamp     
    Glucose AUC 1,059 ± 29 1,018 ± 16 10,099 ± 103 10,097 ± 121 
    Insulin AUC 2,514 ± 358* 4,640 ± 579 29,405 ± 2,746* 52,317 ± 8,020 
    C-peptide AUC 5,897 ± 362* 8,247 ± 904 84,212 ± 5,975* 118,706 ± 14,861 
    C-peptide AUC/insulin AUC 2.58 ± 0.23 1.97 ± 0.19 2.96 ± 0.19* 2.31 ± 0.12 
Arginine stimulation     
    Insulin 4,797 ± 531* 7,687 ± 1,039 15,801 ± 3,495* 33,170 ± 4,681 
    C-peptide 12,177 ± 1,408 15,950 ± 1,585 39,779 ± 7,444* 75,954 ± 7,297 
First-phase AUC
Total AUC
Hyperglycemic clamp     
    Glucose AUC 1,059 ± 29 1,018 ± 16 10,099 ± 103 10,097 ± 121 
    Insulin AUC 2,514 ± 358* 4,640 ± 579 29,405 ± 2,746* 52,317 ± 8,020 
    C-peptide AUC 5,897 ± 362* 8,247 ± 904 84,212 ± 5,975* 118,706 ± 14,861 
    C-peptide AUC/insulin AUC 2.58 ± 0.23 1.97 ± 0.19 2.96 ± 0.19* 2.31 ± 0.12 
Arginine stimulation     
    Insulin 4,797 ± 531* 7,687 ± 1,039 15,801 ± 3,495* 33,170 ± 4,681 
    C-peptide 12,177 ± 1,408 15,950 ± 1,585 39,779 ± 7,444* 75,954 ± 7,297 

Data are means ± SE. Sprague-Dawley rats were treated for 4–5 weeks with M16 (390 mg/kg body wt) mixed in the diet and were subjected to hyperglycemic clamp followed by arginine infusion as described in research design and methods. AUC, area under the glucose (mg/dl × min), insulin (pmol/l × min), and C-peptide (pmol/l × min) curves. Data are for eight nontreated and nine treated rats.

*

Significant compared with respective nontreated parameters (P < 0.05 by Mann-Whitney test).

View Large
TABLE 3

Islet insulin content and pancreas morphometry of rats treated with M16 in vivo

NontreatedM16 treated
Islets’ insulin (ng/5 islets) 2,167 ± 131 1,439 ± 224* 
β-Cell clusters/mm2 1.93 ± 0.12 1.64 ± 0.12 
Mean area (μm2) of large β-cell clusters† 6,543 ± 1,585 6,824 ± 1,175 
β-Cell mass (mg) 9.5 ± 1.3 9.6 ± 0.9 
No. of small β-cell clusters/slide area (β-cell clusters/mm2)‡ 0.99 ± 0.06 0.76 ± 0.13 
NontreatedM16 treated
Islets’ insulin (ng/5 islets) 2,167 ± 131 1,439 ± 224* 
β-Cell clusters/mm2 1.93 ± 0.12 1.64 ± 0.12 
Mean area (μm2) of large β-cell clusters† 6,543 ± 1,585 6,824 ± 1,175 
β-Cell mass (mg) 9.5 ± 1.3 9.6 ± 0.9 
No. of small β-cell clusters/slide area (β-cell clusters/mm2)‡ 0.99 ± 0.06 0.76 ± 0.13 

Data are means ± SE. Sprague-Dawley rats were treated for 4–5 weeks with M16 (390 mg/kg body wt) mixed in the diet. Islets’ insulin content and morphometry were determined as described in research design and methods.

*

Significant compared with respective nontreated parameters (P < 0.05 by Mann-Whitney test).

†

β-Cell clusters >12,000 μm2.

‡

β-Cell clusters containing <10 β-cells per cluster. Data are for five nontreated and six M16-treated rats.

View Large

G.L. and N.M. contributed equally to this work.

J.B.-T. is affiliated with SyndromeX, a company that has partially financed this article’s research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank N. Kaiser (Hebrew University) for the generous gift of rat insulin and for her helpful advice.

1.
Easom RA: Beta-granule transport and exocytosis.
Semin Cell Dev Biol
 
11
:
253
–266,
2000
2.
Dukes ID, Philipson LH: K+ channels: generating excitement in pancreatic β-cells.
Diabetes
 
45
:
845
–853,
1996
3.
Yaney GC, Corkey BE: Fatty acid metabolism and insulin secretion in pancreatic beta cells.
Diabetologia
 
46
:
1297
–1312,
2003
4.
Poitout V: The ins and outs of fatty acids on the pancreatic beta cell.
Trends Endocrinol Metab
 
14
:
201
–203,
2003
5.
Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle.
J Clin Invest
 
93
:
870
–876,
1994
6.
Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ: Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation.
J Clin Invest
 
101
:
1094
–1101,
1998
7.
Liang Y, Buettger C, Berner DK, Matschinsky FM: Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9).
Diabetologia
 
40
:
1018
–1027,
1997
8.
Komatsu M, Yajima H, Yamada S, Kaneko T, Sato Y, Yamauchi K, Hashizume K, Aizawa T: Augmentation of Ca2+-stimulated insulin release by glucose and long-chain fatty acids in rat pancreatic islets: free fatty acids mimic ATP-sensitive K+ channel–independent insulinotropic action of glucose.
Diabetes
 
48
:
1543
–1549,
1999
9.
Warnotte C, Gilon P, Nenquin M, Henquin JC: Mechanisms of the stimulation of insulin release by saturated fatty acids: a study of palmitate effects in mouse β-cells.
Diabetes
 
43
:
703
–711,
1994
10.
Gravena C, Mathias PC, Ashcroft SJ: Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans.
J Endocrinol
 
173
:
73
–80,
2002
11.
Branstrom R, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O: Long chain coenzyme A esters activate the pore-forming subunit (Kir6. 2) of the ATP-regulated potassium channel.
J Biol Chem
 
273
:
31395
–31400,
1998
12.
Yaney GC, Korchak HM, Corkey BE: Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucose-stimulated insulin secretion in clonal beta-cells.
Endocrinology
 
141
:
1989
–1998,
2000
13.
Cheng H, Straub SG, Sharp GW: Protein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin, and PGE2.
Am J Physiol Endocrinol Metab
 
285
:
E287
–E294,
2003
14.
Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M: Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.
Nature
 
422
:
173
–176,
2003
15.
Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI: The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
J Biol Chem
 
278
:
11303
–11311,
2003
16.
Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B: A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
Biochem Biophys Res Commun
 
301
:
406
–410,
2003
17.
Feng DD, Luo Z, Roh SG, Hernandez M, Tawadros N, Keating DJ, Chen C: Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids.
Endocrinology
 
147
:
674
–682,
2006
18.
Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD: Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat.
J Clin Invest
 
97
:
2728
–2735,
1996
19.
McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes.
Diabetes
 
51
:
7
–18,
2002
20.
Sako Y, Grill VE: A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation.
Endocrinology
 
127
:
1580
–1589,
1990
21.
Paolisso G, Gambardella A, Amato L, Tortoriello R, D’Amore A, Varricchio M, D’Onofrio F: Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects.
Diabetologia
 
38
:
1295
–1299,
1995
22.
Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF: Prolonged elevation of plasma free fatty acids impairs pancreatic β-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.
Diabetes
 
49
:
399
–408,
2000
23.
Carpentier A, Zinman B, Leung N, Giacca A, Hanley AJ, Harris SB, Hegele RA, Lewis GF: Free fatty acid-mediated impairment of glucose-stimulated insulin secretion in nondiabetic Oji-Cree individuals from the Sandy Lake community of Ontario, Canada: a population at very high risk for developing type 2 diabetes.
Diabetes
 
52
:
1485
–1495,
2003
24.
Dubois M, Kerr-Conte J, Gmyr V, Bouckenooghe T, Muharram G, D’Herbomez M, Martin-Ponthieu A, Vantyghem MC, Vandewalle B, Pattou F: Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration.
Diabetologia
 
47
:
463
–469,
2004
25.
Joseph JW, Koshkin V, Saleh MC, Sivitz WI, Zhang CY, Lowell BB, Chan CB, Wheeler MB: Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression.
J Biol Chem
 
279
:
51049
–51056,
2004
26.
Unger RH: Lipotoxic diseases.
Annu Rev Med
 
53
:
319
–336,
2002
27.
Bar-Tana J, Rose-Kahn G, Srebnik M: Inhibition of lipid synthesis by beta beta’-tetramethyl-substituted, C14–C22, alpha, omega-dicarboxylic acids in the rat in vivo.
J Biol Chem
 
260
:
8404
–8410,
1985
28.
Bar-Tana J, Ben-Shoshan S, Blum J, Migron Y, Hertz R, Pill J, Rose-Khan G, Witte EC: Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta’,beta’-tetrasubstituted, long-chain dioic acids.
J Med Chem
 
32
:
2072
–2084,
1989
29.
Hertz R, Sheena V, Kalderon B, Berman I, Bar-Tana J: Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators.
Biochem Pharmacol
 
61
:
1057
–1062,
2001
30.
Kalderon B, Sheena V, Shachrur S, Hertz R, Bar-Tana J: Modulation by nutrients and drugs of liver acyl-CoAs analyzed by mass spectrometry.
J Lipid Res
 
43
:
1125
–1132,
2002
31.
Penhos JC, Wu CH, Basabe JC, Lopez N, Wolff FW: A rat pancreas–small gut preparation for the study of intestinal factor(s) and insulin release.
Diabetes
 
18
:
733
–738,
1969
32.
Sutton R, Peters M, McShane P, Gray DW, Morris PJ: Isolation of rat pancreatic islets by ductal injection of collagenase.
Transplantation
 
42
:
689
–691,
1986
33.
Leibowitz G, Oprescu AI, Uckaya G, Gross DJ, Cerasi E, Kaiser N: Insulin does not mediate glucose stimulation of proinsulin biosynthesis.
Diabetes
 
52
:
998
–1003,
2003
34.
Mayorek N, Kalderon B, Itach E, Bar-Tana J: Sensitization to insulin induced by β,β′-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo.
Diabetes
 
46
:
1958
–1964,
1997
35.
Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H: The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse.
Cell Metab
 
1
:
245
–258,
2005
36.
Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD: Role of GPR40 in fatty acid action on the beta cell line INS-1E.
Biochem Biophys Res Commun
 
335
:
97
–104,
2005
37.
Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE: Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion.
J Biol Chem
 
267
:
5802
–5810,
1992
38.
Antinozzi PA, Segall L, Prentki M, McGarry JD, Newgard CB: Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion: a re-evaluation of the long-chain acyl-CoA hypothesis.
J Biol Chem
 
273
:
16146
–16154,
1998
39.
Roduit R, Nolan C, Alarcon C, Moore P, Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, Massie B, Ruderman N, Rhodes C, Poitout V, Prentki M: A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli.
Diabetes
 
53
:
1007
–1019,
2004
40.
Vara E, Tamarit-Rodriguez J: Glucose stimulation of insulin secretion in islets of fed and starved rats and its dependence on lipid metabolism.
Metabolism
 
35
:
266
–271,
1986
41.
Schulze D, Rapedius M, Krauter T, Baukrowitz T: Long-chain acyl-CoA esters and phosphatidylinositol phosphates modulate ATP inhibition of KATP channels by the same mechanism.
J Physiol
 
552
:
357
–367,
2003
42.
Dobbins RL, Chester MW, Stevenson BE, Daniels MB, Stein DT, McGarry JD: A fatty acid-dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion.
J Clin Invest
 
101
:
2370
–2376,
1998
43.
Hosokawa H, Corkey BE, Leahy JL: Beta-cell hypersensitivity to glucose following 24-h exposure of rat islets to fatty acids.
Diabetologia
 
40
:
392
–397,
1997
44.
Ritz-Laser B, Meda P, Constant I, Klages N, Charollais A, Morales A, Magnan C, Ktorza A, Philippe J: Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate.
Endocrinology
 
140
:
4005
–4014,
1999
45.
Jacqueminet S, Briaud I, Rouault C, Reach G, Poitout V: Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration.
Metabolism
 
49
:
532
–536,
2000
46.
Busch AK, Cordery D, Denyer GS, Biden TJ: Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic β-cell function.
Diabetes
 
51
:
977
–987,
2002
47.
Assimacopoulos-Jeannet F: Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes.
Int J Obes Relat Metab Disord
 
28 (Suppl. 4)
:
S53
–S57,
2004
48.
Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F: Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion?
Diabetes
 
50
:
803
–809,
2001
49.
Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang MY, Unger RH, Sherry AD, Newgard CB: Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue.
J Biol Chem
 
279
:
27263
–27271,
2004
50.
Liu YQ, Tornheim K, Leahy JL: Glucose-fatty acid cycle to inhibit glucose utilization and oxidation is not operative in fatty acid-cultured islets.
Diabetes
 
48
:
1747
–1753,
1999
DIABETES
2006